A Phase 2, Prospective, Randomised, Open-Label Study of Defibrotide For The Prevention of Acute Graft-Versus-Host Disease (AGVHD) After Allogeneic Haematopoietic Cell Transplantation (HCT) Meeting Abstract
Industry Collaboration
International Collaboration